drugset
drugset / Trial / NCT00755638

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

NCT00755638 ↗

Phase 1 Completed 48 enrolled Acceleron Pharma, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

Single center, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ACE-031 in healthy postmenopausal volunteers

Timeline

Start
2008-09
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject RAMATERCEPT Protein / enzyme biologic — Subcutaneous

Indications

muscular atrophy